Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Treatment (GnRH Agonists, Intrauterine Devices, Non-hormonal Medications), By Type, By End user, By Region, And Segment Forecasts, 2023 To 2030

Uterine fibroid (UF) are the most common benign tumors in women of childbearing age and the world is witnessing rise in prevalence of disease in women which is the key factor driving the market. In February 2022, Contemporary OB/GYN published an article, ‘A Look At the Current State of Uterine Fibroid Care’ which estimates around 70% of women to develop disease by age to 50. In addition, black race has strongest evidence along with 11 other factors such as genetic susceptibility, age, hypertension, premenopausal status, imbalanced diet and overweight are increasing risk of leiomyoma and driving the Uterine Fibroid Treatment Drugs Market.

Every year July is marked as Fibroid Awareness Month and 1st July is dedicated as National Wear White Day to support leiomyoma affected females. Such initiatives aim to raise awareness, emphasis early diagnosis and educate people about the condition. Moreover, in November 2021, Minerva Surgical, Inc. launched the website educating commons about the uterine health. Thus, government and private organizations are actively taking initiatives to raise the awareness in the society and boosting the space growth.

Uterine Fibroid Treatment Drugs Market is segmented by type as:

• Subserosal 

• Intramural 

• Submucosal 

• Pedunculated 

The space has presence of medications like gonadotropin-releasing hormone (GnRH) agonists and intrauterine devices. Non-hormonal medications include Lysteda, Cyklokapron (Tranexamic acid) and NSAIDs are used for pain management. Moreover, recently approved drugs in space are adding new options for treatment. For instance, in May 2021, FDA approved Pfizer and Myovant Sciences drug Myfembree for treatment of UF associated heavy menstrual bleeding. In addition, there are several drugs under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative opportunities for market growth. For instance, Kissei Pharmaceutical, Co. Ltd.’s drug candidate KLH-2109 is under phase 3 trials indicated for uterine fibroids patient with menorrhagia and pain. 

Key players are undertaking strategic initiatives such as expansion, mergers & acquisitions, new launches, licensing partnerships to increase their market share and further fueling the market growth. For instance, the collaboration between Pfizer, Inc and Myovant Sciences GmbH to bring drug Myfembree in Uterine Fibroid Treatment Drugs Market

Uterine Fibroid Treatment Drugs Market Segmentation

Major companies operating in the space include Myovant Sciences GmbH, Pfizer Inc., Abbvie, Inc., Ferring B.V. AstraZeneca, and Bayer AG among others.